{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:37:50Z","timestamp":1787319470467,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["NCT 03244956"],"award-info":[{"award-number":["NCT 03244956"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PHRC2015"],"award-info":[{"award-number":["PHRC2015"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","physicamedica.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physica Medica"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejmp.2026.105769","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:43:50Z","timestamp":1773899030000},"page":"105769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +\/- dabrafenib followed by radioactive iodine"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8021-1515","authenticated-orcid":false,"given":"Nad\u00e8ge","family":"Anizan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4814-8549","authenticated-orcid":false,"given":"Alexandre","family":"Pignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-1204","authenticated-orcid":false,"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8118-8268","authenticated-orcid":false,"given":"David","family":"Broggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Lamart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmp.2026.105769_b0005","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejmp.2026.105769_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.semnuclmed.2021.11.002","article-title":"Iodine-131 and iodine-131-meta-iodobenzylguanidine dosimetry in cancer therapy","volume":"52","author":"Flux","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0015","first-page":"1132","article-title":"Radioiodine-131 therapy for well-differentiated thyroid cancer\u2014a quantitative radiation dosimetric approach: outcome and validation in 85 patients","volume":"33","author":"Maxon","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12149-021-01655-y","article-title":"I-124 PET\/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response","volume":"36","author":"Plyku","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJM198310203091601","article-title":"Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer","volume":"309","author":"Maxon","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0030","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2967\/jnumed.114.144089","article-title":"Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging","volume":"55","author":"Jentzen","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0035","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2967\/jnumed.115.168799","article-title":"Dose\u2013response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET\/CT","volume":"57","author":"Wierts","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0040","first-page":"171","article-title":"The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer","volume":"87","author":"Benua","year":"1962","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0045","first-page":"1317","article-title":"A method and rationale for treating thyroid carcinoma with the largest safe dose of I-131","volume":"II","author":"Benua","year":"1986","journal-title":"Front Thyroidol"},{"key":"10.1016\/j.ejmp.2026.105769_b0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2967\/jnumed.116.179606","article-title":"Comparison of empiric versus whole-body\/-blood clearance dosimetry\u2013based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer","volume":"58","author":"Deandreis","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0055","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1210\/jc.2011-0494","article-title":"Efficacy of dosimetric versus empiric prescribed activity of 131i for therapy of differentiated thyroid cancer","volume":"96","author":"Klubo-Gwiezdzinska","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejmp.2026.105769_b0060","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2967\/jnumed.115.170571","article-title":"124I PET assessment of response of bone metastases to initial radioiodine treatment of differentiated thyroid cancer","volume":"57","author":"Jentzen","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0065","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejmp.2026.105769_b0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1089\/thy.2018.0457","article-title":"Redifferentiation of a BRAFK601E-mutated poorly differentiated thyroid cancer patient with dabrafenib and trametinib treatment","volume":"29","author":"Leboulleux","year":"2019","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.ejmp.2026.105769_b0075","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","article-title":"Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK Inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejmp.2026.105769_b0080","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.ejmp.2026.105769_b0090","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.122.264913","article-title":"The role of pretherapy quantitative imaging and dosimetry in radioiodine therapy for advanced thyroid cancer","author":"Taprogge","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0095","article-title":"A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p V600E mutated differentiated thyroid cancer","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res CCR-23-0046"},{"key":"10.1016\/j.ejmp.2026.105769_b0100","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2023.0240","article-title":"MERAIODE: a phase II redifferentiation trial with trametinib and 131i in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer","author":"Leboulleux","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.ejmp.2026.105769_b0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","article-title":"Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Rosar","year":"2021","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.ejmp.2026.105769_b0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40658-024-00657-9","article-title":"Accuracy of patient-specific I-131 dosimetry using hybrid whole-body planar-SPECT\/CT I-123 and I-131 imaging","volume":"11","author":"Morphis","year":"2024","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.ejmp.2026.105769_b0115","article-title":"Patient-specific biokinetics and hybrid 2D\/3D approach integration in OEDIPE software: application to radioiodine therapy","author":"Bensiali","year":"2022","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2026.105769_b0120","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/abf276","article-title":"Advanced Monte Carlo simulations of emission tomography imaging systems with GATE","volume":"66","author":"Sarrut","year":"2021","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ejmp.2026.105769_b0125","unstructured":"(2009) ICRP 110: Adult Reference Computational Phantoms."},{"key":"10.1016\/j.ejmp.2026.105769_b0130","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","article-title":"EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations","volume":"45","author":"Gear","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmp.2026.105769_b0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejmp.2026.105769_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v050.i12","article-title":"nparLD: an R software package for the nonparametric analysis of longitudinal data in factorial experiments","volume":"50","author":"Noguchi","year":"2012","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ejmp.2026.105769_b0145","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/bioinformatics\/btv153","article-title":"PRROC: computing and visualizing precision-recall and receiver operating characteristic curves in R","volume":"31","author":"Grau","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmp.2026.105769_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092209","article-title":"Area under precision-recall curves for weighted and unweighted data","volume":"9","author":"Keilwagen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmp.2026.105769_b0155","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/j.ijrobp.2011.03.042","article-title":"Cone-beam CT-based delineation of stereotactic lung targets: the influence of image modality and target size on interobserver variability","volume":"82","author":"Altorjai","year":"2012","journal-title":"Int J Radiat Oncol"}],"container-title":["Physica Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179726000566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179726000566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:44:41Z","timestamp":1776771881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1120179726000566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S1120179726000566"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmp.2026.105769","relation":{},"ISSN":["1120-1797"],"issn-type":[{"value":"1120-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +\/- dabrafenib followed by radioactive iodine","name":"articletitle","label":"Article Title"},{"value":"Physica Medica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmp.2026.105769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Associazione Italiana di Fisica Medica e Sanitaria. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105769"}}